Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Forecasts ‘High Teens’ Growth For Biosimilars

Chairman And CEO Bradway Outlines Expectations For Amgen’s Biosimilars Business

Executive Summary

Amgen expects future growth in the “high teens” for biosimilars, chairman and CEO Bob Bradway told the J.P. Morgan Healthcare Conference this week, also setting out his aspirations for the firm’s biosimilars pipeline.

You may also be interested in...



Amgen’s Amjevita US Sales On The Rise, Oncology Biosimilars Still In Slump

It seems that the first US Humira biosimilar is recovering from the predicted slow uptake, but Amgen’s oncology biosimilars portfolio continues to deteriorate.

Amgen Confirms US Aflibercept Filing As Regeneron Awaits Biocon Trial Fate

Amgen has thrown its hat in the ring to launch a US biosimilar to Regeneron’s Eylea eye-disease blockbuster, as all eyes remain on the outcome of a key patent-infringement trial between Biocon and the originator.

US Amjevita Sales Slide By Almost Two-Thirds

Amgen has revealed a significant – albeit expected – drop in second-quarter sales figures for its Amjevita US biosimilar rival to Humira.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel